Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Crossref DOI link: https://doi.org/10.1007/s40273-016-0457-1
Published Online: 2016-10-22
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kearns, Benjamin
Pandor, Abdullah
Stevenson, Matt
Hamilton, Jean
Chambers, Duncan
Clowes, Mark
Graham, John
Kumar, M. Satish
Funding for this research was provided by:
Health Technology Assessment Programme (15/69/13)
License valid from 2016-10-22